Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues

Journal of Medicinal Chemistry

Volumn 52, Issue 13, 2009, Pages 3982-3993

  Marquis, Robert W ^a   Lago, Amparo M ^a   Callahan, James F ^a   Lee Trout, Robert E ^a   Gowen, Maxine ^a   DelMar, Eric G ^b   Van Wagenen, Bradford C ^b   Logan, Sarah ^b   Shimizu, Scott ^b   Fox, John ^b   Nemeth, Edward F ^b   Yang, Zheng ^a   Roethke, Theresa ^a   Smith, Brian R ^a   Ward, Keith W ^a   Lee, John ^a   Keenan, Richard M ^a   Bhatnagar, Pradip ^a  

^a GLAXOSMITHKLINE   (United States)

^b NPS Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; 2 CHLORO 6 [[3[[1,1 DIMETHYL 2 (2 NAPHTHALENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]OXY]BENZONITRILE; AMINOALCOHOL; BETA ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; ESTRADIOL; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; SB 262470 A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIRALITY; CONTINUOUS INFUSION; CONTROLLED STUDY; COW; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; NONHUMAN; OSSIFICATION; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; AMINO ALCOHOLS; ANIMALS; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE; RATS; RECEPTORS, CALCIUM-SENSING; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 67649977140     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900364m     Document Type: Article

References (62)

1. Iqbal, J.; Inzerillo, A. M.; Moonga, B. S.; Baljit, S.; Zaidi, M. The molecular pharmacology of osteoporosis. Osteoporosis 2003, 569-594.
2. Deal, C. Osteoporosis therapies: bisphosphonates, SERMS, PTH and new therapies. Clin. Rev. Bone Miner. Metab. 2005, 3, 125-141.
3. Rodan, G. A.; Martin, T. J. Therapeutic approaches to bone diseases. Science 2000, 289, 1508-1514.
4. Bodenner, D.; Redman, C.; Riggs, A. Teriparatide in the management of osteoporosis. Clin. Interventions Aging 2007, 2, 499-507.
5. Bilezikian, J. P. Anabolic therepy for osteoporosis. Women's Health 2007, 3, 243-253.
6. Girotra, M.; Rubin, M. R.; Bilezikian, J. P. The use of parathyroid hormone in the treatment of osteoporosis. Rev. Endocrinol. Metab. Disorders 2006, 7, 113-121.
7. Eriksen, E. F.; Robins, D. A. Teriparatide: a bone formation treatment for osteoporosis. Drugs Today 2004, 40, 935-948.
8. Quattrocchi, E.; Kourlas, H. Teriparaitide: a review. Clin. Ther. 2004, 26, 841-854.
9. Dobnig, H. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expt Opin. Pharmacother. 2003, 57, 710-718.
10. Ebling, P. R.; Russell, R. G. G. Teriparaitide (rhPTH1-34) for the treatment of osteoporosis. Int. J. Clin. Pract. 2003, 57, 710-718.
11. Berg, C.; Neumeyer, K.; Kirkpatrick, P. Fresh from the pipline: Teriparatide. Nat. Rev. Drug Discovery. 2003, 2, 257-258.
12. Kronenberg, H. M. PTHrP and skeletal development. Ann. New York Acad. Sci. 2006, 1068, 1-13.
13. Murray, T. M.; Rao, L. G.; Divieti, P.; Bringhurst, F. R. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr. Rev. 2005, 26, 78-113.
14. Gardella, T. J.; Juppner, H. Molecular properties of the PTH/PTHrP receptor. Trends Endocr. Metab. 2001, 12, 210-217.
15. Juppner, H. Receptors for parathyroid hormone and parathyroid hormone-related peptide: exploration of their biological importance. Bone 1999, 25, 87-90.
16. Brown, E. M.; MacLeod, R. J. Extracellular Calcium Sensing and Extracellular Calcium Signaling. Physiol. Rev. 2001, 81, 239-297.
17. Nemeth, E. F. Calcium receptor-dependent regulation of cellular functions. News Physiol. Sci. 1995, 10, 1-5.
18. Brown, E. M.; MacLeod, R. J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 2001, 81, 239-297.
19. Chen, R. A.; Goodman, W. G. Role of the calcium-sensing receptor in parathyroid gland physiology. Am. J. Physiol. Renal Physiol. 2004, 286, F1005-F1011.
20. Tfelt-Hansen, J.; Brown, E. M. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit. Rev. Clin. Lab. Sci. 2005, 42, 35-70.
21. Nemeth, E. F. Misconceptions about calcimimetics. Anns. N. Y. Acad. Sci. 2006, 1068, 471-476.
22. Nemeth, E. F.; Fox, J. Compounds acting on the parathyroid calcium receptor as novel therapies for hyperparathyroidism and osteoporosis. Endocr. Updates 2003, 19, 173-202.
23. Nemeth, E. F. Pharmacological regulation of parathyroid hormone secretion. Curr. Pharm. Des. 2002, 8, 2077-2087.
24. Nemeth, E. F.; Fox, J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endcrinol. Metab. 1999, 10, 66-71.
25. Nemeth, E. F.; Bennett, S. A. Tricking the parathyroid gland with novel calcimimetic agents. Nephrol., Dial., Transplant. 1998, 13, 1923.
26. Locatelli, F.; Pontoriero, G.; Limbardo, M.; Tentori, F. Cinacalcet hydrochloride: calcimimnetic for the treatment of hyperparathyroidism. Exp. Opin. Endocr. Metab. 2006, 1, 167-179.
27. Dong, B. J. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin. Ther. 2005, 27, 1725-1751.
28. de Francisco, A. L. M. Cinacalcet HCL: a novel therapeutic for the treatment of hyperparathyroidism. Exp. Opin. Pharmacother. 2005, 6, 441-452.
29. +2 receptor. antagonists that stimulate secretion of parathyroid hormone. J. Pharm. Exp. Ther. 2001, 299, 323-331.
30. Gowen, M.; Stroup, G. B.; Dodds, R. A.; James, I. E.; Votta, B. J.; Smith, B. R.; Bhatnagar, P. K.; Lago, A. M.; Callahan, J. F.; Del Mar, E. G.; Miller, M. A.; Nemuth, E. F.; Fox, J. Antagonizing the parathyroid calcium receptor stimulates parathyroid secretion and bone formation in osteopenic rats. J. Clin. Invest. 2000, 105, 1595-1604.
31. Arey, B. J.; Seethala, R.; Ma, Z.; Fura, A.; Morin, J.; Swartz, J.; Vyas, V.; Yang, W., Jr.; Feyen, J. H. M. A Novel Calcium-Sensing Receptor Antagonist Transiently Stimulates Parathyroid Hormone Secretion in Vivo. Endocrinology 2005, 5, 1131-1136.
32. 2-(1-aryl)ethyl-3-phenylpropane-1,2- diamines as Novel Calcimimetics Acting on the Calcium Sensing Receptor. Bioorg. Med. Chem. Lett. 2000, 10, 2001-2004.
33. 1-(1-(1-naphthyl)ethyl)-3-phenylpropane- 1,2-diamines and conformationally constrained indole analogs: development of calindol as a new calcimimetic acting at the calcium sensing receptor. Bioorg. Med. Chem. Lett. 2004, 14, 3345-3349.
34. 2-(1-(1- naphthyl)ethyl)-1,2-diaminocyclohexanes: A New Class of Calcilytic Agents Acting at the Calcium-Sensing Receptor. ChemBioChem 2004, 5, 1131-1136.
35. Arey, B. J.; Seethala, R.; Ma, Z.; Fura, A.; Morin, J.; Swartz, J.; Vyas, V.; Yang, W., Jr.; Feyen, J. H. M. A Novel Calcium-Sensing Receptor Antagonist Transiently Stimulates Parathyroid Hormone Secretion in Vivo. Endocrinology 2005, 5, 1131-1136.
36. Yang, W.; Wang, Y.; Roberge, J. Y.; Ma, Z.; Liu, Y.; Lawerence, R. M.; Rotella, D. P.; Seethala, R.; Feyen, J. H. M.; Dickson, J. K., Jr. Discovery and structure-activity relationships of benzylpyrrolidine substituted aryloxypropanols as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 1225-1228.
37. Gavai, A. V.; Vaz, R. J.; Mikkilineni, A. B.; Roberge, J. Y.; Liu, Y.; Lawrence, R. M.; Corte, J. R.; Yang, W.; Bednarz, M.; Dickson Jr, J. K.; Ma, Z.; Seethala, R.; Feyen, J. H. M. Discovery nof novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 5478-5482.
38. Shcherbakova, I.; Balandrin, M. F.; Fox, J.; Ghatak, A.; Heaton, W.; Conklin, R. L. 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg. Med. Chem. Lett. 2005, 15, 1557-1560.
39. Shcherbakova, I.; Huang, G.; Geoffroy, O. J.; Nair, S. K.; Swierczek, K.; Balandrin, M. F.; Fox, J.; Heaton, W. L.; Conklin, R. L. Bioorg. Med. Chem. Lett. 2005, 15, 2537-2540.
40. Dobnig, H.; Turner, R. T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995, 136, 3632-3638.
41. Ishizuya, T.; Yokose, S.; Hori, M.; Noda, T.; Suda, T.; Yoshiki, S.; Yamaguchi, A. Parathyroid hormone exerts disparate effects on osteoclast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 1997, 99, 2961-2970.
42. Frolik, C. A.; Black, E. C.; Cain, R. L.; Satterwhite, J. H.; Brown-Augsburger, P. L.; Sato, M.; Hock, J. M. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003, 33, 372-379.
43. Onyia, J. E.; Helvering, L. M.; Gelbert, L.; Wei, T.; Huang, S.; Chen, P.; Dow, E. R.; Maran, A.; Zhang, M.; Lotinun, S.; Halladay, D. L.; Miles, R. R.; Kulkarni, N. H.; Ambrose, E. M.; Ma, Y. L.; Frolik, C. A.; Sato, M.; Bryant, H. U.; Turner, R. T. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis of DNA microarray. J. Cell. Biochem. 2005, 95, 403-418.
44. Fraher, L. J.; Klein, K.; Marier, R.; Freeman, D.; Hendy, G. N.; Glotzman, D.; Hodsman, A. B. Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. J. Clin. Endocr. Metab. 1995, 80, 60-64.
45. Revel, L.; Sorbera, L. A.; Martin, L. Teriparatide: treatment of osteoporosis parathyroid hormone analog. Drugs Future 2000, 25, 803-808.
46. Nemeth, E. F.; Steffey, M. E.; Hammerland, L. G.; Hung, B. C. P.; van Wagenen, B. C.; DelMar, E. G.; Balandrin, M. F. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4040-4045.
47. Crivori, P.; Poggesi, I. Predictive model for identifying potential CYP2D6 Inhibitors. Basic Clin. Pharm. Toxicol. 2005, 96, 251-253.
48. Ekins, S.; Gianpaolo, B.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Winkel, J. H.; Wrighton, S. A. Three- and four dimensional-quantitative structure-activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999, 9, 477-489.
49. De Groot, M. J.; Ackland, M. J.; Horne, V. A.; Alex, A. A.; Jones, B. C. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 1999, 42, 1515-1524.
50. Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon, V. R.; Oxbrow, A. K.; Lewis, C. J.; Tennant, M. G.; Modi, S.; Eggleston, D. S.; Chenery, R. J.; Bridges, A. M. Crystal structure of the human cytochrome P450 2D6. J. Biol. Chem. 2006, 281, 7614-7622.
51. Mitcheson, J. S. hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem. Res. Toxicol. 2008, 21, 1005-1010.
52. Kramer, C.; Beck, B.; Kriegel, J. M.; Clark, T. A composite model for hERG blockade. ChemMedChem 2008, 3, 254-265.
53. Stansfeld, P. J.; Gedeck, P.; Gosling, M.; Cox, B.; Mitcheson, J. S.; Sutcliffe, M. J. Drug block of the hERG potassium channel: insights from modeling. Proteins: Struct., Funct., Bioinf. 2007, 68, 568-580.
54. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440, 463-469.
55. Sanguinetti, M. C.; Mitcheson, J. S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26, 119-124.
56. Fernandez, D.; Ghanta, A.; Kauffman, G. W.; Sanguinetti, M. C. Physiochemical features of the hERG channel binding site. J. Biol. Chem. 2004, 279, 10120-10127.
57. Tonioli, C.; Crisma, M.; Formaggio, F.; Peggion, C. Control of peptide conformation by the Thorpe-Ingold effect (C-α tetrasubstitution). Biopolymers 2001, 60, 396-419.
58. The conformational search of global energy minima for analogs 7 and 22 were carried out using the BatchMin module in Maestro. The conformational space was explored by 2000 iterations of Monte Carlo multiple minimum (MCMM) torsional angle sampling procedure in BatchMin, and the energy of each conformation was determined by the OPLS-2005 force field in GB/SA water solvation model.
59. Easson, L. H.; Stedman, E. Studies on the relationship between chemical constitution and physiological action. V. Molecular dissymmetry and physiological activity. Biochem. J. 1933, 31, 1257-1266.
60. Testa, B. Mechanisms of chiral recognition in pharmacology. Acta Pharm. Nord. 1990, 2, 137-143.
61. Ruffolo, Jr., R. R. Chirality in α-and β-adrenoreceptor agonists and antagonists. Tetrahedron 1991, 47, 9953-9980.
62. Rogers, K.; Dunn, C.; Hebert, S.; Brown, E.; Nemeth, E. Pharmacological comparison of bovine parathyroid, human parathyroid, and rat kidney calcium receptors expressed in HEK 293 cells. J. Bone Miner. Res. 1995, 10 (Suppl. 1), S483.